[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.151.150. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 325
Citations 0
Observation
December 2016

Resolution of Porphyria Cutanea Tarda in Patients With Hepatitis C Following Ledipasvir-Sofosbuvir Combination Therapy

Author Affiliations
  • 1Department of Dermatology, University of California, San Diego
  • 2Center For Clinical Studies, Houston, Texas
  • 3University of Texas Medical Branch, Galveston
  • 4Department of Dermatology, University of Texas Health Science Center at Houston
JAMA Dermatol. 2016;152(12):1393-1395. doi:10.1001/jamadermatol.2016.3036

Porphyria cutanea tarda (PCT) is the most common porphyria, caused by a decrease in uroporphyrinogen decarboxylase (UROD) activity.1 There is a strong association between the sporadic form of PCT and hepatitis C virus (HCV) infection. Depending on the country, 40% to 50% of patients with PCT have been found to be infected with HCV.2 Chronic hepatitis C infection unmasks the UROD enzyme deficiency in genetically predisposed patients by causing oxidative stress from iron overload.3 In addition, PCT occurs in the highest rates in patients with HCV-related liver cirrhosis, which suggests that cirrhosis may play a role in disease development.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×